Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Genetic and epigenetic alterations play a decisive role in the onset of several human neoplasms. Mutations and polymorphisms are two frequent genetic alterations. Located on chromosome 19 (19p13.11), the NIS SLC5A5 (solute carrier family 5 member 5) gene encodes a highly specialized and efficient 80–90 kDa transmembrane glycoprotein that mediates active transport of iodide from the bloodstream into the follicular cells. Given the highly significant role of NIS in the physiology and the cancer pathogenesis process, this paper's objective is to provide a comprehensive assessment of the associations between NIS gene and protein with papillary thyroid cancer.
Thyroid cancer is the most prevalent endocrine neoplasia in the world. The use of mathematical models on the development of tumors has yielded numerous results in this field and modeling with differential equations is present in many papers on cancer. In order to know the use of mathematical models with differential equations or similar in the study of thyroid cancer, studies since 2006 to date was reviewed. Systems with ordinary or partial differential equations were the means most frequently adopted by the authors. The models deal with tumor growth, effective half-life of radioiodine applied after thyroidectomy, the treatment with iodine-131, thyroid volume before thyroidectomy, and others. The variables usually employed in the models includes tumor volume, thyroid volume, amount of iodine, thyroglobulin and thyroxine hormone, radioiodine activity, and physical characteristics such as pressure, density, and displacement of the thyroid molecules. In conclusion, the mathematical models used so far with differential equations approach several aspects of thyroid cancer, including participation in methods of execution or follow-up of treatments. With the development of new models, an increase in the current understanding of the detection, evolution, and treatment of diseases is a step that should be considered.
Objetivo: Analisar a associação entre os polimorfismos dos genes IFNG e IL4 com o CPT, e suas características clínicas Método: Foram coletados o sangue de 30 pacientes portadores de CPT, e de 82 controles saudáveis. A genotipagem se deu através da técnica de PCR qualitativa. Os resultados foram cruzados com os níveis de TSH e Tiroglobulina dos pacientes com CPT e analisados com o programa SPSS 25.0. O estudo teve aprovação no comitê de ética sob CAAE 57382416.6.0000. 0023. Resultados: O genótipo AA do +874 A/T IFNG apresentou frequência de 60% nos participantes com CPT, nos controles o genótipo TA apareceu em 55,6%, o valor de significância foi p=0,0038. Em relação ao IL4, o genótipo B2/B2 foi o mais comum em ambos os grupos com significância de p=0,271. As amostras estavam em equilíbrio HW. Em relação as medianas de Tiroglobulina (ng/mL) e TSH (uUI/mL), foram observados os seguintes valores de significância respectivamente: p=0,612 e p=0,419 em relação ao IFNG e p= 0,431 e p=0,655, em relação ao IL4. Conclusão: Houve associação estatística com o polimorfismo +874 A/T IFNG e o CPT, entretanto não houve associação entre os níveis de TSH e tiroglobulina em pacientes com CPT. Em relação ao gene IL4 não foram observados significância entre a frequência genotípica e o CPT e os níveis de TSH e Tiroglobulina. O presente trabalho reforça a necessidade da produção de mais estudos acerca do tema a fim de estabelecer-se se de fato é possível afirmar se tais associações (ou ausência de associação) são de fato realidade no contexto do CPT.
Thyroid cancer is the most common endocrine cancer in the world. Noting that the NOS3 gene polymorphism interferes with nitric oxide production, this study aims to identify and analyze the NOS3 gene polymorphism in the intron 4 region in patients with papillary thyroid cancer. A case-control study was conducted with 31 papillary thyroid cancer patients of both genders who underwent thyroidectomy and treatment with sodium iodide radiopharmaceutical (131I) compared with 81 control patients. Through papillary thyroid cancer, the results were observed, compiled, and analyzed using SPSS version 25.0. The significance level of 5% was adopted. Genotypic frequencies of healthy subjects were in the Hardy-Weinberg equilibrium ( P = 0.503). There was a significant genotypic difference between papillary thyroid cancer and healthy individuals ( P <0.001). The BB genotype conferred a protective factor for papillary thyroid cancer ( P <0.001, odds ratio (OR) 0.16; 95% confidence interval (CI) 0.06, 0.42), while the presence of the A allele appears to be a risk factor for papillary thyroid cancer ( P <0.001, OR 3.54; 95% CI 1.86, 6.73). The intron 4 polymorphism of the NOS3 gene was associated with susceptibility to papillary thyroid cancer. Thus, future research into the effects of this polymorphism is essential.
Introduction Papillary thyroid cancer corresponds to approximately 1% of all carcinomas; nevertheless, it is the most prevalent endocrine neoplasm in the world. Studies reveal that the BAX (−248 G > A) polymorphism may be associated with negative regulation of BAX gene transcription activity, causing a decrease in its protein expression. Objective The present study aimed to describe the genotype and allele frequencies of BAX single nucleotide polymorphisms (−248 G > A) (rs4645878) in the research patients, and to associate its presence with susceptibility to papillary thyroid cancer. Methods This case-control study was conducted with 30 patients with papillary thyroid cancer. For the evaluation of genetic polymorphisms, the polymerase chain reaction-restriction fragment length polymorphism technique was employed. Allele and genotype frequencies were estimated using the SPSS program, and significant associations were considered when p < 0.05. Results There was a significant genotypic difference between papillary thyroid cancer and the control group (p = 0.042). The GG genotype provided a protective factor for papillary thyroid cancer (p = 0.012, odds ratio (OR) = 0.313; confidence interval (CI) = 0.123–0.794). Likewise the G allele was a protective factor for papillary thyroid cancer (p = 0.009; OR = 0.360; CI = 0.163–0.793). The BAX gene polymorphism (−248 G > A) was associated with papillary thyroid cancer. Conclusion BAX (−248 G > A) GG genotype carriers, or at least one mutated allele, was associated with papillary thyroid cancer in the Brazilian population studied, and the G allele presence is considered a protective factor against papillary thyroid cancer occurrence.
The incidence of thyroid cancer is rising all over the world, and the papillary subtype (PTC) is the primary factor for this increase. The presence of thyroid tumors is commonly associated with increased levels of cytokines, such as interleukin 6 (IL-6). Considering PTC patients treated with thyroidectomy and radioactive iodine [Formula: see text]I (RAI), we propose an ordinary differential system using four variables: the RAI activity, the number of cancer cells and the serum concentrations of IL-6 and thyroglobulin (Tg). Our objective is to study the efficacy of different therapeutic doses of RAI in the treatment of thyroid cancer. The Allee effect is taken into account when modeling cancer cells growth under the influence of IL-6. From the results obtained, the main factors and conditions correlated with successful treatment, such as the RAI activity used and the tumor response are addressed. The detection of minimal doses of RAI that can cause tumor extinction is performed, though this has also meant longer periods for tumor cell elimination. The critical number of tumor cells due to the Allee effect is analyzed and linked to the immune system or biological factors that can slow the progression of the tumor but are insufficient after thyroid resection surgery.
Objetivo: Associar a presença do SNP IL1B -511 (rs16944) à susceptibilidade ao CPT, bem como comparar níveis séricos da citocina antes e sete dias após a Iodoterapia, juntamente com outras características clínicas dos pacientes. Método: Trata-se de um estudo caso-controle, no qual foram obtidas amostras de sangue de 52 indivíduos (26 em cada grupo). A genotipagem foi realizada por meio da estratégia PCR-RFLP. Os níveis séricos de IL-1β foi medido por meio de kit para ensaio imunoenzimático (ELISA). Testes para médias e estudos de associação foram executados considerando-se um nível de significância de 5%. Resultados: Não houve diferença estatística com relação a distribuição genotípica entre indivíduos caso e controle, e estes grupos não diferiram em relação às dosagens de citocina. Porém, os níveis de citocina aumentaram significativamente após a Iodoterapia, sendo que os portadores do genótipo CC apresentaram maior produção da proteína, mas este aumento não estava correlacionado com a dose de radiofármaco administrada. Conclusão: O polimorfismo IL1B -511 não foi associado à susceptibilidade ao CPT, porém os níveis séricos da citocina elevaram-se com o tratamento da iodoterapia, e esta elevação foi genótipo dependente.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.